4.7 Article

Initial Development and Validation of a Novel Extraction Method for Quantitative Mining of the Formalin-Fixed, Paraffin-Embedded Tissue Proteome for Biomarker Investigations

期刊

JOURNAL OF PROTEOME RESEARCH
卷 10, 期 2, 页码 896-906

出版社

AMER CHEMICAL SOC
DOI: 10.1021/pr100812d

关键词

Formalin-fixed paraffin-embedded (FFPE) tissue; proteomics; label-free quantitation; renal cell carcinoma; tissue biomarkers; biomarker discovery; archival tissue

资金

  1. Cancer Research UK
  2. UK Department of Health
  3. St. James's University Hospital
  4. Medical Research Council [G0802416] Funding Source: researchfish
  5. MRC [G0802416] Funding Source: UKRI

向作者/读者索取更多资源

Annotated formalin-fixed, paraffin-embedded (FFPE) tissue archives constitute a valuable resource for retrospective biomarker discovery. However, proteomic exploration of archival tissue is impeded by extensive formalin-induced covalent cross-linking. Robust methodology enabling proteomic profiling of archival resources is urgently needed. Recent work is beginning to support the feasibility of biomarker discovery in archival tissues, but further developments in extraction methods which are compatible with quantitative approaches are urgently needed. We report a cost-effective extraction methodology permitting quantitative proteomic analyses of small amounts of FFPE tissue for biomarker investigation. This surfactant/heat-based approach results in effective and reproducible protein extraction in FFPE tissue blocks. In combination with a liquid chromatography-mass spectrometry-based label-free quantitative proteomics methodology, the protocol enables the robust representative and quantitative analyses of the archival proteome. Preliminary validation studies in renal cancer tissues have identified typically 250-300 proteins per 500 ng of tissue with 1D LC-MS/MS with comparable extraction in FFPE and fresh frozen tissue blocks and preservation of tumor/normal differential expression patterns (205 proteins, r = 0.682; p < 10(-15)). The initial methodology presented here provides a quantitative approach for assessing the potential suitability of the vast FFPE tissue archives as an alternate resource for biomarker discovery and will allow exploration of methods to increase depth of coverage and investigate the impact of preanalytical factors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Hematology

Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial

Charlotte Pawlyn, David A. Cairns, Tom Menzies, John R. Jones, Matthew W. Jenner, Gordon Cook, Kevin D. Boyd, Mark T. Drayson, Martin F. Kaiser, Roger G. Owen, Walter Gregory, Gareth J. Morgan, Graham H. Jackson, Faith E. Davies

Summary: Autologous stem cell transplant (ASCT) is the standard of care for consolidation after induction therapy in newly diagnosed myeloma patients. While older patients may have a reduced progression-free survival after ASCT, the treatment is well tolerated regardless of age. Data from clinical trials and real-world practice suggest that ASCT can benefit selected older myeloma patients.

HAEMATOLOGICA (2022)

Letter Hematology

Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors

David John Allsup, Zoe Craig, David Cairns, Dena Howard, Anna Hockaday, Adrian Bloor, Zarni Soe, Christopher Pepper, Valter Gattei, Antonella Zucchetto, Pauline Robbe, Ruth Clifford, Anna Schuh, Talha Munir, Andrew Rawstron, Peter Hillmen

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Meeting Abstract Hematology

Multistate Models Demonstrate That Lenalidomide Maintenance Enhances Survival By Prolonging Time in First Remission for Patients Treated in the UK NCRI Myeloma XI Randomised Trial

Zoe Craig, Christopher Parrish, Charlotte Pawlyn, Martin F. Kaiser, Catherine Olivier, John R. Jones, Mark T. Drayson, Roger G. Owen, Matthew W. Jenner, Gordon Cook, Walter Martin Gregory, Faith E. Davies, Gareth J. Morgan, Graham Jackson, David Cairns

Meeting Abstract Hematology

Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment

Hannah Victoria Giles, Mark T. Drayson, Nicola Wright, Gordon Cook, Faith E. Davies, Gareth J. Morgan, Ruth M. de Tute, Roger GOwen, David Cairns, Anna Hockaday, Tom Menzies, Martin F. Kaiser, Charlotte Pawlyn, Graham Jackson, Guy Pratt

Article Hematology

Redefining nonmeasurable multiple myeloma using mass spectrometry

Hannah Giles, Mark A. Cook, Mark Trehane Drayson, Gordon Cook, Nicola Jane Wright, Simon John North, Stephen Harding, David A. Cairns, Anna Hockaday, Martin F. Kaiser, Paul Moss, Faith E. Davies, Gareth J. Morgan, Graham Jackson, Guy Pratt

Article Oncology

Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma

Jessica Caro, David Cairns, Tom Menzies, Eileen Boyle, Charlotte Pawlyn, Gordon Cook, Martin Kaiser, Brian A. Walker, Roger Owen, Graham H. Jackson, Gareth J. Morgan, Jennifer Heaney, Mark Drayson, Faith E. Davies

Summary: Immunoparesis is associated with poor survival in myeloma. This study demonstrates that the etiologic cytogenetic abnormality influences the degree and clinical impact of immunoparesis in newly diagnosed patients in a large clinical trial. The depth of IgM immunoparesis can be used to further risk-stratify hyperdiploid patients for future clinical decisions.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Article Oncology

Frailty and treatment outcome in advanced gastro-oesophageal cancer: An exploratory analysis of the GO2 trial

Jessica Pearce, Daniel Swinson, David Cairns, Sherena Nair, Mark Baxter, Russell Petty, Matt Seymour, Peter Hall, Galina Velikova

Summary: Frailty measures, such as GO2FS, mCFS, and G8, are significantly associated with treatment outcomes in frail patients with cancer, providing evidence for optimal care.

JOURNAL OF GERIATRIC ONCOLOGY (2022)

Article Oncology

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

Ruth M. de Tute, Charlotte Pawlyn, David A. Cairns, Faith E. Davies, Tom Menzies, Andy Rawstron, John R. Jones, Anna Hockaday, Rowena Henderson, Gordon Cook, Mark T. Drayson, Matthew W. Jenner, Martin F. Kaiser, Walter M. Gregory, Gareth J. Morgan, Graham H. Jackson, Roger G. Owen

Summary: This study found that MRD status at ASCT + 3 and ASCT + 9 is a powerful predictor of PFS and OS in patients with multiple myeloma. Lenalidomide maintenance therapy can increase the likelihood of converting from MRD-positive to MRD-negative. However, high-risk molecular features still have a negative impact on PFS and OS.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

Mattia D'Agostino, David A. Cairns, Juan Jose Lahuerta, Ruth Wester, Uta Bertsch, Anders Waage, Elena Zamagni, Maria-Victoria Mateos, Daniele Dall'Olio, Niels W. C. J. van de Donk, Graham Jackson, Serena Rocchi, Hans Salwender, Joan Blade Creixenti, Bronno van der Holt, Gastone Castellani, Francesca Bonello, Andrea Capra, Elias K. Mai, Jan Durig, Francesca Gay, Sonja Zweegman, Michele Cavo, Martin F. Kaiser, Hartmut Goldschmidt, Jesus Maria Hernandez Rivas, Alessandra Larocca, Gordon Cook, Jesus F. San-Miguel, Mario Boccadoro, Pieter Sonneveld

Summary: In this study, the Revised International Staging system (R-ISS) for intermediate-risk multiple myeloma patients was revised based on the additive value of each single risk feature.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Medicine, General & Internal

Frailly-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma X.V Trial)): a study protocol for a randomised phase III trial

Amy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, David A. Cairns, Anna Hockaday, Jennifer Bird, Stella Bowcock, Martin Kaiser, Ruth de Tute, Neil Rabin, Kevin Boyd, John Jones, Christopher Parrish, Hayley Gardner, David Meads, Bryony Dawkins, Catherine Olivier, Rowena Henderson, Phillip Best, Roger Owen, Matthew Jenner, Bhuvan Kishore, Mark Drayson, Graham Jackson, Gordon Cook

Summary: Multiple myeloma is a bone marrow cancer that mainly affects older people, and its incidence is increasing in an ageing population. Older, less fit patients who are ineligible for stem cell transplant have shown less improvement in patient outcomes over the last 10 years. Research is needed to improve treatment tolerability, clinical outcomes, and quality of life in this patient group.

BMJ OPEN (2022)

Article Biophysics

Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study

John A. Snowden, Sam H. Ahmedzai, Angela Cox, David A. Cairns, A. John Ashcroft, Cathy Williams, Jamie D. Cavenagh, Anna Hockaday, Julia M. Brown, Ian W. Brock, Treen C. M. Morris, Gordon Cook

Summary: The Myeloma X trial explored the relationship between genetics and patient-reported outcomes in multiple myeloma patients. The study identified several single nucleotide polymorphisms (SNPs) associated with pain and health-related quality-of-life scores. These findings support previous genome-wide association studies linking SNPs to subjective parameters in multiple myeloma.

BONE MARROW TRANSPLANTATION (2022)

Article Hematology

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial

Matthew W. Jenner, Charlotte Pawlyn, Faith E. Davies, Tom Menzies, Anna Hockaday, Catherine Olivier, John R. Jones, Kamuraj Karunanithi, Jindriska Lindsay, Bhuvan Kishore, Gordon Cook, Mark T. Drayson, Martin F. Kaiser, Roger G. Owen, Walter Gregory, David A. Cairns, Gareth J. Morgan, Graham H. Jackson

Summary: Lenalidomide is an effective maintenance therapy for myeloma patients, but the addition of vorinostat did not provide additional benefits in terms of progression-free survival and overall survival compared to lenalidomide alone.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Medicine, General & Internal

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial

Kara-Louise Royle, Amy Beth Coulson, Karthik Ramasamy, David A. Cairns, Anna Hockaday, Sergio Quezada, Mark Drayson, Martin Kaiser, Roger Owen, Holger W. Auner, Gordon Cook, David Meads, Catherine Olivier, Lorna Barnard, Rhiannon Lambkin, Andrea Paterson, Bryony Dawkins, Mike Chapman, Guy Pratt, Rakesh Popat, Graham Jackson, Ceri Bygrave, Jonathan Sive, Ruth de Tute, Andrew Chantry, Christopher Parrish, Mark Cook, Samir Asher, Kwee Yong

Summary: This study is a multicenter, risk-adapted, response-guided, open-label, randomized controlled trial for patients with multiple myeloma. It includes different treatment strategies and adjusts the treatment based on the risk profile of the patients.

BMJ OPEN (2022)

Meeting Abstract Oncology

A biomarker enrichment trial of anti-EGFR agents in right primary tumor location (rPTL), RAS wild-type (RAS-wt) advanced colorectal cancer (aCRC): ARIEL (ISRCTN11061442)

Christopher Williams, Jake Emmerson, Andrew David Beggs, Nicholas West, John A. Bridgewater, Janet Graham, Matthew T. Seymour, Gemma Hemmings, Claire Dimbleby, Geraldine A. Murden, Alexandra Gilbert, David M. Meads, David A. Cairns, Richard Adams, Jenny F. Seligmann

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Hematology

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy were associated with a prior History of Hypertension or Cardiac Disease and the use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

Talha Munir, Alexandra Pitchford, Adrian Bloor, Angus Broom, Moya Young, Ben Kennedy, Renata Walewska, Michelle Furtado, Gavin Preston, Jeff Neilson, Nicholas Pemberton, Gamal Sidra, Nicholas Morley, Kate Cwynarski, Anna Schuh, Francesco Forconi, Simona Gatto, Shankara Paneesha, Christopher Fox, Dena Howard, Anna Hockaday, David Cairns, Sharon Jackson, Natasha Greatorex, Piers E. M. Patten, David Allsup, Peter Hillmen

BRITISH JOURNAL OF HAEMATOLOGY (2022)

暂无数据